Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Ben George

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6263-5891; OpenAlex author ID A5103232405. Sources: OpenAlex.

Their work

Papers
34 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2014: 2 papers · 2015: 5 papers · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 7 papers · 2021: 7 papers · 2022: none · 2023: 3 papers · 2024: 2 papers

Papers 34

  1. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  2. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  3. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Co-author DOI 10.1002/jso.27265↗
  4. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  5. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  6. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Co-author DOI 10.1007/s10555-021-09993-z↗
  7. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Co-author DOI 10.1016/j.amjsurg.2020.12.001↗
  8. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.soc.2021.06.004↗
  9. Precision Medicine and Pancreatic Cancer. Co-author DOI 10.1016/j.soc.2021.06.008↗
  10. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.06.038↗
  11. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09149-3↗
  12. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.754687↗
  13. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? Co-author DOI 10.1007/s11605-019-04423-6↗
  14. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.03.022↗
  15. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  16. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. First author DOI 10.1097/sla.0000000000003049↗
  17. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-0099↗
  18. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
  19. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  20. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  21. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07906-7↗
  22. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002957↗
  23. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
  24. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Co-author DOI 10.1016/j.prro.2017.06.013↗
  25. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? Co-author DOI 10.1002/jso.24361↗
  26. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.surg.2015.09.018↗
  27. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. Co-author DOI 10.1200/jop.2016.016162↗
  28. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.06.017↗
  29. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. Co-author DOI 10.1111/hpb.12325↗
  30. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. Co-author DOI 10.1111/hpb.12448↗
  31. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Mult… First author DOI 10.1245/s10434-015-4649-2↗
  32. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. Co-author DOI 10.3978/j.issn.2078-6891.2015.053↗
  33. Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s11605-014-2635-9↗
  34. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2014.09.010↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Douglas B. Evans · 30 shared papers, 2014–2024 · strength 2.80
  2. Susan Tsai · 30 shared papers, 2014–2024 · strength 2.80
  3. Bradley A. Erickson · 28 shared papers, 2014–2024 · strength 2.67
  4. Kathleen K. Christians · 28 shared papers, 2014–2024 · strength 2.59
  5. William Adrian Hall · 19 shared papers, 2017–2024 · strength 2.17
  6. Mohammed Aldakkak · 15 shared papers, 2015–2024 · strength 1.64
  7. Mandana Kamgar · 10 shared papers, 2020–2024 · strength 1.46
  8. Callisia Nathelee Clarke · 12 shared papers, 2017–2024 · strength 1.39
  9. Paul S. Ritch · 19 shared papers, 2014–2020 · strength 1.33
  10. Kulwinder S. Dua · 8 shared papers, 2018–2024 · strength 0.88
  11. Ashley N. Krepline · 10 shared papers, 2014–2021 · strength 0.81
  12. Naveen M. Kulkarni · 5 shared papers, 2020–2023 · strength 0.60
  13. Parag P. Tolat · 7 shared papers, 2015–2023 · strength 0.59
  14. Chad A. Barnes · 6 shared papers, 2017–2020 · strength 0.53
  15. Sam Z. Thalji · 3 shared papers, 2023 · strength 0.48
  16. Sakti Chakrabarti · 2 shared papers, 2021–2024 · strength 0.36
  17. Rebecca Y. Kim · 2 shared papers, 2021 · strength 0.24
  18. Fabian Mc. Johnston · 5 shared papers, 2014–2016 · strength 0.24
  19. D. Wittmann · 2 shared papers, 2020 · strength 0.19
  20. Neil R. Jariwalla · 2 shared papers, 2019–2020 · strength 0.18
  21. Catherine E. Hagen · 2 shared papers, 2019–2020 · strength 0.18
  22. Saryleine Ortiz de Choudens · 1 shared paper, 2024 · strength 0.17
  23. Paul C. Cockrum · 1 shared paper, 2021 · strength 0.17
  24. Saryn Doucette · 1 shared paper, 2023 · strength 0.16
  25. Thomas B. McFall · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.